Comments (1)
No. 1-1
MedMaven
MedMaven

Editor

Lartruvo (olaratumab; Lilly) will be withdrawn from the market following results from the phase 3 ANNOUNCE study which showed that the treatment, when combined with doxorubicin, did not improve survival in patients with advanced or metastatic soft tissue sarcoma (STS) compared with doxorubicin alone.

Lilly is working to establish an access program to provide Lartruvo to patients who wish to continue treatment, after consultation with their physicians; new patients, outside of those in clinical trials, should not be initiated on Lartruvo.